Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
- None.
- None.
Net revenue increased to
Increases 2023 revenue guidance range to
Conference call to be hosted today at 8:30 a.m. ET
Total net revenue was
“We are extremely pleased with our results in the second quarter of 2023. Building on three successful quarters in a row, this represents our most successful quarter to date from a net revenue perspective,” said Peter Greenleaf, President, and Chief Executive Officer of Aurinia. “Strong commercial execution continues as we see further utilization of LUPKYNIS® (voclosporin) across the lupus nephritis marketplace. Moreover, we are excited by the depth of usage in nephrology and the continued expansion into rheumatology. Our marketing and selling efforts continue to produce patient start forms (PSFs), patients on therapy (POT), wallets shipped, and net product revenue at or near all-time highs.”
For the fiscal year 2023, the Company is increasing its net product revenue guidance to a range of
Second Quarter 2023 and Recent Highlights
- Arthritis & Rheumatology published full results of AURORA 2, a Phase 3, double-blind, placebo-controlled extension study out to 3 years, demonstrating that kidney preservation, sustained renal response, and reductions in steroid use were achieved with LUPKYNIS with mycophenolate mofetil (MMF) and low-dose steroids, compared to MMF and low-dose steroids alone.
- A post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies presented at the annual meetings of the European League Against Rheumatism (EULAR) and the European Renal Association (ERA) found that LUPKYNIS with MMF and low-dose steroids resulted in significantly higher renal response rates and earlier and greater reductions in proteinuria in LN patients with high proteinuria, compared to MMF and low-dose steroids alone.
-
Refined method of use patent (‘991) was issued by the
U.S. Patent and Trademark Office and Orange Book listed.
-
Received reimbursement recommendation from National Institute for Health and Care Excellence (NICE) in the
United Kingdom , Swissmedic marketing authorization inSwitzerland and most recently reimbursement approval inItaly .
- Initiated strategic review of the company in association with J.P. Morgan Securities LLC as our financial advisor.
LUPKYNIS Product Performance Highlights
-
There were approximately 1,911 patients on LUPKYNIS therapy at June 30, 2023, compared with 1,274 at June 30, 2022, representing an increase of approximately
50% year over year.
-
Aurinia added 451 patient start forms (PSFs) during the three months ended June 30, 2023, compared to 409 during the three months ended June 30, 2022, representing an increase of approximately
10% over the previous period last year.
- As of July 31, 2023, the Company recorded approximately 1,017 PSFs since January 1, 2023.
-
Conversion rates remain consistent with more than
89% of PSFs converted to patients on therapy.
-
Time to convert has improved to an all-time high with the large majority (
65% ) of patients on therapy by 20 days.
-
As of June 30, 2023, 12 month persistency improved to
54% from51% at March 31, 2023.
Financial Results for the Three and Six Months Ended June 30, 2023
Total net revenue was
Total cost of sales and operating expenses for the three months ended June 30, 2023 and June 30, 2022 were
Cost of sales were
Gross margin for the three months ended June 30, 2023 and June 30, 2022 was approximately
Selling, general and administrative (SG&A) expenses, inclusive of share-based compensation, were
Non-cash SG&A share-based compensation expense included within SG&A expenses was
Research and development (R&D) expenses, inclusive of share-based compensation, were
Non-cash R&D share-based compensation expense included with R&D expense was
Other (income) expense, net was
Interest expense was
Interest income was
For the three months ended June 30, 2023, Aurinia recorded a net loss of
Financial Liquidity at June 30, 2023
As of June 30, 2023, Aurinia had cash, cash equivalents and restricted cash and short-term investments of
Aurinia believes that it has sufficient financial resources to fund its operations, which include funding commercial activities, such as FDA related post approval commitments, manufacturing and packaging of commercial drug supply, funding its supporting commercial infrastructure, advancing its R&D programs and funding its working capital obligations for at least the next few years.
This press release is intended to be read in conjunction with the Company’s unaudited condensed consolidated financial statements and Management's Discussion and Analysis for the quarter ended June 30, 2023 in the Company’s Quarterly Report on Form 10-Q and the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, including risk factors disclosed therein, which will be accessible on Aurinia's website at www.auriniapharma.com, on SEDAR at www.sedarplus.ca or on EDGAR at www.sec.gov/edgar.
Conference Call Details
Aurinia will host a conference call and webcast to discuss the quarter ended June 30, 2023 financial results today, Thursday, August 3, 2023 at 8:30 a.m. ET. The audio webcast can be accessed under “News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. In order to participate in the conference call, please dial +1 (888) 645-4404 (Toll-free
About Lupus Nephritis
Lupus Nephritis is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in
Forward-Looking Statements
Certain statements made in this press release may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable
Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Aurinia to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following: Aurinia’s actual future financial and operational results may differ from its expectations; difficulties Aurinia may experience in completing the commercialization of voclosporin; the market for the LN business may not be as estimated; Aurinia may have to pay unanticipated expenses; Aurinia may not be able to obtain sufficient supply to meet commercial demand for voclosporin in a timely fashion; unknown impact and difficulties imposed by the widespread health concerns on Aurinia’s business operations including nonclinical, clinical, regulatory and commercial activities; the results from Aurinia’s clinical studies and from third party studies and reports may not be accurate; Aurinia’s third party service providers may not, or may not be able to, comply with their obligations under their agreements with Aurinia; regulatory bodies may not grant approvals on conditions acceptable to Aurinia and its business partners, or at all; there can be no assurance that the initiated strategic review will result in Aurinia pursuing a particular transaction or other strategic outcome in a timely manner, or at all; and Aurinia’s assets or business activities may be subject to disputes that may result in litigation or other legal claims. Although Aurinia has attempted to identify factors that would cause actual actions, events, or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results, performances, achievements, or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond Aurinia’s control. There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information. All forward-looking information contained in this press release is qualified by this cautionary statement. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
||||||||
(unaudited) |
|
June 30,
|
|
December 31,
|
||||
|
|
|
|
|
||||
ASSETS |
|
|
|
|
||||
Current assets |
|
|
|
|
||||
Cash, cash equivalents and restricted cash |
|
$ |
81,707 |
|
|
$ |
94,172 |
|
Short-term investments |
|
|
269,006 |
|
|
|
295,218 |
|
Accounts receivable, net |
|
|
19,499 |
|
|
|
13,483 |
|
Inventories, net |
|
|
33,155 |
|
|
|
24,752 |
|
Prepaid expenses |
|
|
11,332 |
|
|
|
13,580 |
|
Other current assets |
|
|
1,208 |
|
|
|
1,334 |
|
Total current assets |
|
|
415,907 |
|
|
|
442,539 |
|
|
|
|
|
|
||||
Non-current assets |
|
|
|
|
||||
Other non-current assets |
|
|
1,518 |
|
|
|
13,339 |
|
Property and equipment, net |
|
|
3,650 |
|
|
|
3,650 |
|
Acquired intellectual property and other intangible assets, net |
|
|
5,683 |
|
|
|
6,425 |
|
Finance right-of-use asset, net |
|
|
117,428 |
|
|
|
— |
|
Operating right-of-use assets, net |
|
|
4,714 |
|
|
|
4,907 |
|
Total assets |
|
$ |
548,900 |
|
|
$ |
470,860 |
|
|
|
|
|
|
||||
LIABILITIES |
|
|
|
|
||||
Current liabilities |
|
|
|
|
||||
Accounts payable and accrued liabilities |
|
|
41,375 |
|
|
|
39,990 |
|
Deferred revenue |
|
|
3,228 |
|
|
|
3,148 |
|
Other current liabilities |
|
|
2,088 |
|
|
|
2,033 |
|
Finance lease liability |
|
|
14,016 |
|
|
|
— |
|
Operating lease liabilities |
|
|
954 |
|
|
|
936 |
|
Total current liabilities |
|
|
61,661 |
|
|
|
46,107 |
|
|
|
|
|
|
||||
Non-current liabilities |
|
|
|
|
||||
Finance lease liability |
|
|
79,422 |
|
|
|
— |
|
Operating lease liabilities |
|
|
6,814 |
|
|
|
7,152 |
|
Deferred compensation and other non-current liabilities |
|
|
8,711 |
|
|
|
12,166 |
|
Total liabilities |
|
|
156,608 |
|
|
|
65,425 |
|
SHAREHOLDER’S EQUITY |
|
|
|
|
||||
Common shares - no par value, unlimited shares authorized, 143,369 and 142,268 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively |
|
|
1,196,480 |
|
|
|
1,185,309 |
|
Additional paid-in capital |
|
|
98,832 |
|
|
|
85,489 |
|
Accumulated other comprehensive loss |
|
|
(1,020 |
) |
|
|
(1,061 |
) |
Accumulated deficit |
|
|
(902,000 |
) |
|
|
(864,302 |
) |
Total shareholders' equity |
|
|
392,292 |
|
|
|
405,435 |
|
Total liabilities and shareholders' equity |
|
$ |
548,900 |
|
|
$ |
470,860 |
|
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) |
||||||||||||||||
|
|
Three months ended |
|
Six months ended |
||||||||||||
|
|
June 30, |
|
June 30, |
||||||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
|
|
(unaudited) |
||||||||||||||
Revenue |
|
|
|
|
|
|
|
|
||||||||
Product revenue, net |
|
$ |
41,100 |
|
|
$ |
28,148 |
|
|
$ |
75,437 |
|
|
$ |
49,640 |
|
License, royalty and collaboration revenue |
|
|
394 |
|
|
|
43 |
|
|
|
466 |
|
|
|
176 |
|
Total revenue, net |
|
|
41,494 |
|
|
|
28,191 |
|
|
|
75,903 |
|
|
|
49,816 |
|
Operating expenses |
|
|
|
|
|
|
|
|
||||||||
Cost of sales |
|
|
1,563 |
|
|
|
1,599 |
|
|
|
1,984 |
|
|
|
1,855 |
|
Selling, general and administrative |
|
|
47,081 |
|
|
|
51,532 |
|
|
|
97,205 |
|
|
|
96,729 |
|
Research and development |
|
|
12,650 |
|
|
|
11,525 |
|
|
|
25,808 |
|
|
|
24,145 |
|
Other (income) expense, net |
|
|
(3,630 |
) |
|
|
(476 |
) |
|
|
(3,340 |
) |
|
|
958 |
|
Total cost of sales and operating expenses |
|
|
57,664 |
|
|
|
64,180 |
|
|
|
121,657 |
|
|
|
123,687 |
|
Loss from operations |
|
|
(16,170 |
) |
|
|
(35,989 |
) |
|
|
(45,754 |
) |
|
|
(73,871 |
) |
Interest expense |
|
|
(65 |
) |
|
|
— |
|
|
|
(65 |
) |
|
|
— |
|
Interest income |
|
|
4,101 |
|
|
|
483 |
|
|
|
7,915 |
|
|
|
745 |
|
Net loss before income taxes |
|
|
(12,134 |
) |
|
|
(35,506 |
) |
|
|
(37,904 |
) |
|
|
(73,126 |
) |
Income tax (benefit) expense |
|
|
(642 |
) |
|
|
9 |
|
|
|
(206 |
) |
|
|
19 |
|
Net loss |
|
$ |
(11,492 |
) |
|
$ |
(35,515 |
) |
|
$ |
(37,698 |
) |
|
$ |
(73,145 |
) |
Basic and diluted loss per share |
|
$ |
(0.08 |
) |
|
$ |
(0.25 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.52 |
) |
Weighted-average common shares outstanding used in computation of basic and diluted loss per share |
|
|
142,777 |
|
|
|
141,726 |
|
|
|
142,904 |
|
|
|
141,734 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230803258324/en/
Investors/Media:
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
FAQ
What was Aurinia Pharmaceuticals' net revenue for the second quarter of 2023?
What was the growth rate of net revenue for Aurinia Pharmaceuticals compared to the prior year second quarter?